Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Chongqing Zhifei Biological Products (300122 CH)
Watchlist
93
Analysis
Health Care
•
China
Chongqing Zhifei Biological Products Company Ltd. researches, manufactures, and sells vaccines and biological products including prevention products, blood products, diagnostic reagents, and therapeutic agents.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Thematic (Sector/Industry)
•
11 Sep 2022 09:08
China Healthcare Weekly(Sep9)-Innovative Device Policy,Commercial Success Definition,Don't Be Fooled
We recommend cautiously optimistic about new innovative device policy. It's important to clarify what constitutes "commercialization success". All...
Xinyao (Criss) Wang
Follow
336 Views
Share
bullish
•
CanSino Biologics
•
01 Sep 2022 08:39
CanSino Biologics (6185.HK/688185.CH) 2022H1 - It's Too Early to Be Completely Bearish on CanSino
The market has exaggerated the impact of performance decline of COVID-19 vaccine on CanSino. Although 2022 is a difficult year, considering MCV2...
Xinyao (Criss) Wang
Follow
243 Views
Share
bullish
•
CanSino Biologics
•
09 May 2022 08:49
CanSino Biologics (688185.CH/6185.HK) -Difficulties in 2022 Cannot Mask Long-Term Investment Value
2022 will be difficult for CanSino. We lowered performance forecast.But due to strong R&D and technology platforms, the value of CanSino's pipeline...
Xinyao (Criss) Wang
Follow
321 Views
Share
bearish
•
Chongqing Zhifei Biological Products
•
18 Apr 2022 08:55
Chongqing Zhifei Biological Products (300122.CH) - WHO's One-Dose HPV Vaccine Regimen & The Outlook
WHO’s recommendation on HPV vaccines is not the biggest risk of Zhifei and won't affect short-term performance, but the valuation logic...
Xinyao (Criss) Wang
Follow
402 Views
Share
bullish
•
Jiangsu Recbio Technology
•
17 Mar 2022 15:19
RecBio (江苏瑞科) Pre-IPO: Thoughts on Valuation
Recbio is pre-marketing its USD 100-200m Hong Kong IPO. In this insight, we provide our thoughts on valuation for the company.
Ke Yan, CFA, FRM
Follow
337 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x